Drug intelligence / Profile preview

KD5040

Development stage: Preclinical
Lead developer: Kyung Hee University
Administration: Oral

Overview

**KD5040** is an experimental modified Korean herbal medicine formula developed for Parkinson's disease research. It is prepared as a 3:1:1 mixture of Chunggantang, *Eugenia caryophyllata* and *Pogostemon cablin*. In MPTP-induced mouse models of Parkinson's disease, KD5040 showed neuroprotective and motor-function benefits; co-administration with levodopa improved motor outcomes at lower levodopa doses and reduced levodopa-induced dyskinesia measures. These findings are preclinical and do not establish clinical efficacy in people. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC6907061/))

Other names: modified Chunggan formulamodified Chunggantang

Targets

PPP1R1B (Protein phosphatase 1 regulatory inhibitor subunit 1B)

Beyond the preview

Go deeper on KD5040.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KD5040.

Explore the full profile